Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGrey market Mounjaro refers to tirzepatide that enters the UK outside the licensed, regulated supply chain — not necessarily counterfeit, but not subject to the quality controls or clinical oversight that a GPhC-registered pharmacy must meet. It is still a prescription-only medicine under UK law, and obtaining or supplying it without a valid prescription is unlawful regardless of the source country. If you have found tirzepatide being sold via a website, a social-media group, or a private seller without any clinical consultation attached, that is the grey market in practice. Understanding what that means for your safety is worth a few minutes of your time.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the scenario: you search for Mounjaro, skip past the pharmacy pages, and land on a listing with a price that looks considerably more attractive. There is no consultation form, no prescriber mentioned, no GPhC number to check. The seller says the product is genuine, sourced from abroad, and will arrive discreetly.
This is the grey market. The product may genuinely contain tirzepatide (that is what distinguishes it from a straightforward counterfeit) but it has bypassed every safeguard that exists precisely because this medicine is not sold over a counter. Licensed UK pharmacies source tirzepatide through Eli Lilly's authorised supply chain, store pens within strictly controlled cold-chain conditions, and only dispense against a valid prescription. Grey market sellers do none of those things reliably, and in many cases do none of them at all.
One misconception worth clearing up gently: some people assume that if a medicine is genuinely tirzepatide, it is automatically safe to use. The compound itself is only part of the picture. A pen that has been stored incorrectly for a week can degrade. A dose taken without a prescriber knowing your medical history carries risks that no product label can mitigate. The medicine being real does not make the transaction safe.
You can read more about how to assess tirzepatide's clinical profile in full on our dedicated overview page.
Grey market tirzepatide moves through channels that are designed to avoid scrutiny. Social media groups, messaging apps, and lightly regulated online marketplaces are the most common routes. Sellers often present themselves as operating abroad legally and exporting to UK buyers, a framing that sounds reassuring but does not resolve the UK legal position. Mounjaro is a Prescription-Only Medicine here. Importing a POM for personal use without a prescription from a UK-registered prescriber sits in murky legal territory at best, and enforcement has tightened considerably.
MHRA enforcement data tells a clear story. Around 20 million doses of illegally traded weight-loss medicines, valued at approximately £45 million, were seized during 2025 operations. An illicit manufacturing site producing counterfeit tirzepatide pens was raided in Northampton in October 2025. The products seized were not all identical fakes, some were genuine medicines from overseas markets that had been diverted into UK distribution. If you want to understand more about tirzepatide grey market supply, including how diverted stock differs from outright counterfeits, that page sets out the distinction clearly. Grey market and counterfeit are different categories, but the enforcement infrastructure treats both as the same public health problem, and rightly so.
For a closer look at how grey market tirzepatide specifically circulates through messaging-app channels, the grey market tirzepatide and Telegram page covers that particular route in detail.
The MHRA has also issued public guidance on GLP-1 medicines, which you can read on GOV.UK, and suspicious sellers can be reported through the MHRA's Yellow Card scheme.
Tirzepatide pens are refrigerated at 2–8°C until use. That requirement exists because the peptide structure degrades outside those conditions, not dramatically, not visibly, but measurably. A pen that has sat in a warm parcel for two days looks identical to one that has been stored correctly. You cannot see the difference. You will not taste it. The only protection is knowing, with certainty, where the pen has been and who is accountable for its journey.
Licensed pharmacies in the UK operate within a cold-chain framework that is audited by the GPhC. Every pharmacy on the register can be verified at the GPhC's register, and checking that number takes about thirty seconds. Grey market sellers have no equivalent accountability. If a pen arrives degraded, there is no regulated body to complain to and no clinical record that anything went wrong.
The clinical context matters equally. Tirzepatide interacts with oral contraceptives during the first four weeks of use and after each dose increase, women taking the pill should add a non-oral method during those windows, as NHS guidance explains. A grey market transaction involves no prescriber who knows that. Nobody checks whether a buyer has a history of pancreatitis, a condition that affects suitability. Nobody monitors what happens next. If you have come across mounjaro market.com or similar sites and are wondering whether they represent a legitimate route to treatment, that page explains exactly what those platforms are and why they fall outside regulated supply. For more detail on what the full cost of Mounjaro through a regulated route actually covers (including clinical oversight) that page sets it out plainly.
The only lawful route to Mounjaro for weight management in the UK is a prescription issued by a registered prescriber following a clinical assessment. That is not a bureaucratic hurdle placed in front of patients, it is the mechanism by which a clinician confirms that tirzepatide is appropriate for your situation, identifies contraindications, establishes a starting dose, and creates a record that protects you if something changes.
At nume, sorry, at nume, that consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician, on the same day. Identity is verified with photo ID, current weight is confirmed on a live video call, and the prescriber reviews your full health picture before any medicine is prescribed. The Mounjaro overview page walks through the licensed treatment in full, and the weight-loss treatment options page covers how different approaches compare if you are still weighing your choices.
If you are looking at grey market tirzepatide because the legitimate route feels opaque or slow, that is worth knowing about, and our FAQs page covers the most common questions about access and process. The consultation itself is free. If our prescribers find that Mounjaro is right for you, treatment is dispatched the same day and arrives by DPD the next working day. Check your eligibility by starting that conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.